BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia

Monday, March 6, 2023 1 min read

Key Takeaway: BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia

Full Press Release Details

BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia.